<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=57550&amp;fmt=gif">

Life Sciences Insights: CI State of Play

Dawn Faint

|

July 26, 2018

  • CI remains a function that is valued by Life Sciences companies
  • Top tier companies have an average of team size of 11 professionals
  • CI primarily sits under Marketing and Strategy departments

Recently Cipher partnered with undergraduate students in the College of Integrated Science and Technology at James Madison University (JMU) to benchmark how companies in three segments (Pharma, Biotech, Medical Device) of the Life Sciences industry view, resource, and execute competitive intelligence.

Here are the top five insights for Life Sciences and why they matter:

  1. There are over 500 CI professionals in the Top 300 Life Sciences companies, of which pharmaceutical companies account for 44% of the CI workforce
  2. Roche maintains the largest CI team in the industry, followed by Pfizer and Regeneron
    1. These “Top 3” CI organizations have an average team size of 11 professionals
    2. The average CI team size across the Top 300 organizations is two
  3. CI is a priority in 7-in-10 Top Life Sciences companies, while 40% of Senior and Executive Leadership in these companies focus on CI as a core priority
  4. Strategy and Marketing departments house 61% of CI professionals across the Top 300 Life Sciences companies
  5. Business and Marketing are the most prevalent Bachelor’s degrees while Biology and Chemistry are the most prevalent industry-specific Bachelor’s degrees amongst Life Sciences CI professionals

Download the Study

The finding that Pharma companies comprise the bulk of hiring in Life Sciences is no surprise.  The size and scope of global Pharma clinical development programs requires the continuous monitoring of competitors. 

The gap in staffing between the Top 3 organizations and others is significant.  In the survey, the top tier organizations allocated more resources to their CI functions than the others.  In a time of disruption, these additional resources placed strategically around the organization could mean the difference between success or obsolescence.

Where CI should sit in a corporate setting has been a matter of debate for years.  A positive development in the survey results is that approximately 10% of Life Sciences companies are including CI on Innovation teams.  Since these teams are formed to map the strategy of their companies well into the future, it is critical for CI to have a seat at the table.

For additional insights from this benchmarking study, stay tuned later this year for the full report and download your copy of the Executive Summary today to be among the first to receive the full report. 

Download the Study


Subscribe to the Cipher Competitive Strategy Blog to receive instant or weekly notifications when new content is posted. 

Subscribe


Subscribe to Email Updates

Dawn Faint
Dawn Faint

Dawn helps companies in the Life Sciences space map their competitive environment, develop intelligence strategies which identify risks, and position them for future growth. Prior to joining Cipher, Dawn worked for many years in the Healthcare space in leadership roles at Cigna, Schering-Plough, Pharmacia (now Pfizer) and Johnson & Johnson companies Ortho Biotech and Ortho-McNeil, and in the Management Consulting space for Right Management.

Find me on: